ImmunoCellular is a L.A.-based clinical stage company developing immune-based therapies for the treatment of brain and other cancers.
ImmunoCellular’s pipeline includes:
- a Stem-to-T-cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells;
- ICT-121, a patient-specific, dendritic cell-based immunotherapy targeting CD133 found in recurrent glioblastoma;
- ICT-140, a patient-specific, dendritic cell-based immunotherapy targeting ovarian cancer.
- ImmunoCellular recently suspended further patient randomization in its phase 3 trial of ICT-107 in HLA-A2 patients while it pursues a collaborative arrangement or acquisition of its ICT-107 program.
ICT-107 is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. ImmunoCellular recently suspended further patient randomization in its phase 3 trial of ICT-107 in HLA-A2 patients while it pursues a collaborative arrangement or acquisition of its ICT-107 program.
ICT-121 is a DC immunotherapeutic that targets CD133, an antigen commonly associated with cancer stem cells (CSCs). They are conducting a 20-patient Phase 1 clinical trial in patients with recurrent glioblastoma.
ICT-140 is a DC immunotherapeutic that targets seven different antigens associated with ovarian cancer, including those expressed by CSCs. A phase 2 trial is awaiting a partnership or other financing to proceed.
ImmunoCellular Therapeutics’ proprietary cancer immunotherapy technology has the potential to transform the treatment of cancer by improving survival and offering safer and more effective treatment than conventional cancer therapies. Their dendritic cell (DC)-based immunotherapies utilize multiple tumor-specific antigens to target cancer stem cells and other tumor cells by triggering a powerful antitumor immune system response. Their proprietary manufacturing process produces multiple doses from a single apheresis and offers the advantages of potency, versatility, efficiency, cost-effectiveness and convenience compared with earlier generation cancer immunotherapeutics.
ImmunoCellular’s goal is to become an industry-leading, independent, commercial-stage cancer immunotherapy company. They have a development pipeline of therapeutically important, commercially attractive product candidates, and a highly productive, proprietary cancer immunotherapy platform. These assets have the potential to transform the treatment of cancer, benefit patients and create value for their stakeholders.
For more on ImmunoCellular, visit the company’s website.
